| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/28/2011 | US20110098253 Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use |
| 04/28/2011 | US20110098248 Modulators of toll-like receptors |
| 04/28/2011 | US20110098242 Methods and Compositions for Diagnosing and Treating Cervical Intraepithelial Neoplasia and Cervical Cancer |
| 04/28/2011 | US20110098241 Rapamycin analogs as anti-cancer agents |
| 04/28/2011 | US20110098237 Methods for inhibiting drug degradation |
| 04/28/2011 | US20110098236 Diamide inhibitors of cytochrome p450 |
| 04/28/2011 | US20110098235 Antineoplastic peptides |
| 04/28/2011 | US20110098234 Breast cancer proteins |
| 04/28/2011 | US20110098233 Hla-a* 1101-restricted wt1 peptide and pharmaceutical composition comprising the same |
| 04/28/2011 | US20110098232 Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis |
| 04/28/2011 | US20110098226 Small molecular weight TNF receptor multimeric molecule |
| 04/28/2011 | US20110098224 Protein kinase c peptide modulators of angiogenesis |
| 04/28/2011 | US20110098221 INHIBITORS OF Akt ACTIVITY |
| 04/28/2011 | US20110098219 System for Curing Hepatic Cancer with Leptin |
| 04/28/2011 | US20110098213 Novel peptides for use in the treatment of obesity |
| 04/28/2011 | US20110098211 Muteins with tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same |
| 04/28/2011 | US20110098191 In vitro methods for detecting renal cancer |
| 04/28/2011 | US20110097423 Gene Prognosis Predictor Signature for Colorectal Carcinoma |
| 04/28/2011 | US20110097403 Extracellular matrix compositions for the treatment of cancer |
| 04/28/2011 | US20110097394 Type a gelatin capsule containing pufa in free acid form |
| 04/28/2011 | US20110097389 P53 biomarkers |
| 04/28/2011 | US20110097388 Methods of Expressing Proteins with Disulfide Bridges |
| 04/28/2011 | US20110097367 Monolithic in-situ cross-linked alginate implants |
| 04/28/2011 | US20110097364 Macrocyclic lactone compounds and methods for their use |
| 04/28/2011 | US20110097349 Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| 04/28/2011 | US20110097346 Dendritic Cells |
| 04/28/2011 | US20110097345 Novel dosing regimen and method of treatment |
| 04/28/2011 | US20110097344 Compositions, Methods for Treatment, and Diagnoses of Autoimmunity-Related Disorders and Methods for Making Such Compositions |
| 04/28/2011 | US20110097343 Diagnosis and therapy of hematological malignancies |
| 04/28/2011 | US20110097340 Fully human anti-vegf antibodies and methods of using |
| 04/28/2011 | US20110097339 Compositions monovalent for CD28 binding and methods of use |
| 04/28/2011 | US20110097337 Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells |
| 04/28/2011 | US20110097335 Abc transporter protein expression inhibitor |
| 04/28/2011 | US20110097333 Therapeutic and diagnostic agents |
| 04/28/2011 | US20110097329 Compositions and methods for treating cancer and modulating stress granule formation |
| 04/28/2011 | US20110097323 Her2/neu-Specific Antibodies and Methods of Using Same |
| 04/28/2011 | US20110097322 Partially loaded antibodies and methods of their conjugation |
| 04/28/2011 | US20110097321 Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
| 04/28/2011 | US20110097320 4-aminoquinazoline derivatives and methods of use thereof |
| 04/28/2011 | US20110097315 Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one and salts thereof, useful in the treatment of cancer |
| 04/28/2011 | US20110097314 Method for producing a composition for promoting survival of transplanted hematopoietic stem cell |
| 04/28/2011 | US20110097305 Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors |
| 04/28/2011 | US20110097299 Swellable and degradable microspheres |
| 04/28/2011 | US20110097280 Intracorporeal Medicaments for Photodynamic Treatment of Disease |
| 04/28/2011 | US20110097276 Diagnosis of Prostate Cancer |
| 04/28/2011 | US20110097275 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| 04/28/2011 | US20110097268 Radiohaloimatinibs and methods of their synthesis and use in pet imaging of cancers |
| 04/28/2011 | US20110097266 Bombesin Analog Peptide Antagonist Conjugates |
| 04/28/2011 | US20110097261 Amigo-2-inhibitors for treating, diagnosing or detecting cancer |
| 04/28/2011 | DE102009049551A1 Use of the active substance propyphenazone for the therapeutic treatment of tumor, where the active substance inhibits the growth of tumor cells and/or degenerates the tumor cells |
| 04/28/2011 | DE102009049211A1 Sulfoxide Sulfoxides |
| 04/28/2011 | DE102009043260A1 Pyridinyl-imidazolonderivate Pyridinyl-imidazolone derivatives |
| 04/28/2011 | CA2814958A1 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent |
| 04/28/2011 | CA2779309A1 Method for treating androgen receptor positive cancers |
| 04/28/2011 | CA2779282A1 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment |
| 04/28/2011 | CA2779233A1 Combination cancer therapy with hsp90 inhibitory compounds |
| 04/28/2011 | CA2778707A1 Cancer immunotherapy and method of treatment |
| 04/28/2011 | CA2778401A1 Integrin alpha 8-beta 1-specific monoclonal antibody |
| 04/28/2011 | CA2778291A1 Akt inhibitors |
| 04/28/2011 | CA2777902A1 Compounds |
| 04/28/2011 | CA2777881A1 Pyrazolopyrimidine derivatives |
| 04/28/2011 | CA2777430A1 Substituted benzosulphonamides |
| 04/28/2011 | CA2777304A1 Substituted benzosulphonamides |
| 04/28/2011 | CA2777071A1 Substituted halophenoxybenzamide derivatives |
| 04/28/2011 | CA2777019A1 Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity |
| 04/28/2011 | CA2775924A1 Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
| 04/28/2011 | CA2775009A1 Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors |
| 04/28/2011 | CA2774032A1 Anti-gcc antibody molecules and related compositions and methods |
| 04/28/2011 | CA2773356A1 Compositions and methods for treating inflammation and fibrosis |
| 04/28/2011 | CA2771817A1 Modulators of hepatocyte growth factor activator |
| 04/28/2011 | CA2765748A1 Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof |
| 04/27/2011 | EP2314716A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 04/27/2011 | EP2314712A1 Expression vectors encoding epitopes of antigens and methods for their design |
| 04/27/2011 | EP2314630A1 Method of producing immunogenic lipopeptides comprising T-helper and Cytotoxic T Lymphocyte (CTL) epitopes |
| 04/27/2011 | EP2314628A1 Anti-cd27 antibody |
| 04/27/2011 | EP2314624A2 Human antibody molecules for IL-13 |
| 04/27/2011 | EP2314612A2 Differential in tumour gene products and use of same |
| 04/27/2011 | EP2314611A2 Differential in tumour gene products and use of same |
| 04/27/2011 | EP2314610A2 Differential in tumour gene products and use of same |
| 04/27/2011 | EP2314609A1 Metastin derivative and use thereof |
| 04/27/2011 | EP2314601A1 Anti-inflammatory compounds and uses thereof |
| 04/27/2011 | EP2314590A1 Substituted quinolones and methods of use |
| 04/27/2011 | EP2314322A1 Compositions containing genetically modified lung cancer cells expressing a TGF-beta inhibitor |
| 04/27/2011 | EP2314318A1 CD80 antibody for use in combination with chemotherapeutics to treat B cell malignancies |
| 04/27/2011 | EP2314317A2 Anti-glypican 3 antibody |
| 04/27/2011 | EP2314315A1 A blocking monoclonal antibody to the human alpha1 I-domain of VLA-1, and its use for the treatment of inflammatory disorders |
| 04/27/2011 | EP2314308A1 Use of microproteins as tryptase inhibitors |
| 04/27/2011 | EP2314301A2 Sensitization of chemotherapeutic agent-resistant neoplastic cells with various viruses |
| 04/27/2011 | EP2314297A1 Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
| 04/27/2011 | EP2314294A2 3,3'-diindolylmethane immune activating compositions |
| 04/27/2011 | EP2313779A2 Use of defensin alpha 1 and/or defensin alpha 4, as a marker for predicting treatment response and/or a relapse in a patient suffering from chronic myeloid leukaemia |
| 04/27/2011 | EP2313528A2 Methods for the cytological analysis of cervical cells |
| 04/27/2011 | EP2313437A1 Cancerous disease modifying antibodies |
| 04/27/2011 | EP2313426A1 Novel protease inhibitors |
| 04/27/2011 | EP2313414A2 Kinase inhibitors and methods of use |
| 04/27/2011 | EP2313411A1 5h-pyrr0l0 [2,3-b]pyrazine derivatives for kinase modulation, and indications therefor |
| 04/27/2011 | EP2313407A1 cMET INHIBITORS |
| 04/27/2011 | EP2313403A2 Thiazolyl piperdine derivatives |
| 04/27/2011 | EP2313399A1 Thiophene or thiazole derivatives and their use as pi3k inhibitors |
| 04/27/2011 | EP2313398A1 Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof |